Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Total Liabilities (2018 - 2025)

Quantum Biopharma's Total Liabilities history spans 8 years, with the latest figure at $6.1 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 9.29% to $6.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.1 million, a 9.29% decrease, with the full-year FY2025 number at $6.1 million, down 9.29% from a year prior.
  • Total Liabilities hit $6.1 million in Q4 2025 for Quantum Biopharma, down from $6.6 million in the prior quarter.
  • Over the last five years, Total Liabilities for QNTM hit a ceiling of $13.2 million in Q2 2025 and a floor of $3.7 million in Q3 2024.
  • Historically, Total Liabilities has averaged $7.0 million across 5 years, with a median of $6.6 million in 2025.
  • Biggest five-year swings in Total Liabilities: plummeted 41.98% in 2023 and later skyrocketed 163.62% in 2025.
  • Tracing QNTM's Total Liabilities over 5 years: stood at $8.8 million in 2021, then decreased by 10.91% to $7.9 million in 2022, then tumbled by 41.98% to $4.6 million in 2023, then skyrocketed by 46.29% to $6.7 million in 2024, then fell by 9.29% to $6.1 million in 2025.
  • Business Quant data shows Total Liabilities for QNTM at $6.1 million in Q4 2025, $6.6 million in Q3 2025, and $13.2 million in Q2 2025.